{"url_path":"/sec/isco/8-k/2026-07-16/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1355790/0001683168-26-005555-index.html","accession_number":"0001683168-26-005555","cik":"0001355790","ticker":"ISCO","issuer_name":"International Stem Cell CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/1355790/0001683168-26-005555-index.html","primary_entity_key":"0001355790","primary_entity_name":"International Stem Cell CORP"},"word_count":177,"has_tables":true,"body_markdown":"**Item 9.01**\n**Financial Statements and Exhibits.**\n\n** **\n\n**(d) Exhibits**\n\n \n \n \n\n**Exhibit**\n\n**Number**\n\n \n\n**Description**\n\n \n \n\n2.1†\n \n[Membership Interest Purchase Agreement, dated July 10, 2026, by and among International Stem Cell Corporation, International Stem Cell Corporation, Lifeline Cell Technology, LLC, a California limited liability company, and American Type Culture Collection, Inc.](intlstemcell_ex0201.htm)\n\n \n \n \n\n10.1\n \n[Form of Support Agreement](intlstemcell_ex1001.htm)\n\n \n\n104\n\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n \n \n\n†\n \nSchedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules so furnished\n\n \n\n \n\n \n\n \n\n \n\n \n\n 3 \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**INTERNATIONAL STEM CELL CORPORATION**\n\n \n \n \n\n \n \n \n\n \nBy:\n/s/ Russell Kern\n\n \n \nRussell Kern\n\n \n \n\nExecutive Vice President, Chief Scientific Officer and\n\nPrincipal Financial Officer\n\n \n\nDated:\nJuly 16, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 4"}